Misplaced Pages

Docirbrutinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyNext edit →Content deleted Content addedVisualWikitext
Revision as of 04:18, 2 January 2025 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,846 edits created drug stubTag: nowiki added  Revision as of 07:49, 2 January 2025 edit undoIdoghor Melody (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers34,278 editsm clean up, added orphan tagTag: AWBNext edit →
Line 1: Line 1:
{{Orphan|date=January 2025}}

{{cs1 config|name-list-style=vanc|display-authors=6}} {{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
Line 18: Line 20:
| widthR = | widthR =
| altR = | altR =
| captionLR = | captionLR =


<!-- Clinical data --> <!-- Clinical data -->
Line 39: Line 41:
| ATC_prefix = | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =


<!-- Legal status --> <!-- Legal status -->
Line 60: Line 62:
| legal_UN = | legal_UN =
| legal_UN_comment = | legal_UN_comment =
| legal_status = | legal_status =


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 70: Line 72:
| elimination_half-life = | elimination_half-life =
| duration_of_action= | duration_of_action=
| excretion = | excretion =


<!-- Identifiers --> <!-- Identifiers -->
Line 123: Line 125:
] ]
] ]


{{pharma-stub}} {{pharma-stub}}

Revision as of 07:49, 2 January 2025

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2025)

Pharmaceutical compound
Docirbrutinib
Clinical data
Other namesAS-1763
Identifiers
IUPAC name
  • 2--7H-pyrrolopyrimidin-4-yl]-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoroisoquinolin-1-one;methanesulfonic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC35H39FN6O9S2
Molar mass770.85 g·mol
3D model (JSmol)
SMILES
  • CS(=O)(=O)O.CS(=O)(=O)O.C1CC1C2=CC(=C3C(=C2)C=CN(C3=O)C4=CC=CC(=C4CO)C5=C6C=C(NC6=NC(=N5)N)C7=CCN(CC7)C8COC8)F
InChI
  • InChI=InChI=1S/C33H31FN6O3.2CH4O3S/c34-26-13-21(18-4-5-18)12-20-8-11-40(32(42)29(20)26)28-3-1-2-23(25(28)15-41)30-24-14-27(36-31(24)38-33(35)37-30)19-6-9-39(10-7-19)22-16-43-17-22;2*1-5(2,3)4/h1-3,6,8,11-14,18,22,41H,4-5,7,9-10,15-17H2,(H3,35,36,37,38);2*1H3,(H,2,3,4)
  • Key:KMLXYMRUQMJKLA-UHFFFAOYSA-N

Docirbrutinib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective Bruton's tyrosine kinase (BTK) inhibitor that targets chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

References

  1. Kawahata W, Asami T, Kiyoi T, Irie T, Kashimoto S, Furuichi H, et al. (October 2021). "Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase". Journal of Medicinal Chemistry. 64 (19): 14129–14141. doi:10.1021/acs.jmedchem.1c01279. PMID 34529443.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: